The reported statements, read against the company's own industry.
What stands out
Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
2.13BCNY
319.05M · vs all stocks (USD)
Updated Oct 24, 2026
Revenue (TTM)
219.42MCNY
32.91M · vs all stocks (USD)
Updated Oct 24, 2026
Profit Margin
-39.51%
vs Biotechnology peers
Updated Oct 24, 2026
Beta
0.7730x
vs all stocks
Updated Oct 24, 2026
52-Week Change
-33.01%
vs all stocks
Updated Oct 24, 2026
Market Capitalization
2.13BCNY
319.05M · vs all stocks (USD)
Updated Oct 24, 2026
Enterprise Value
1.37BCNY
205.90M · vs all stocks (USD)
Updated Oct 24, 2026
Price to Sales (TTM)
9.69x
vs Biotechnology peers
Updated Oct 24, 2026
Price to Book (MRQ)
1.58x
vs Biotechnology peers
Updated Oct 24, 2026
Enterprise to Revenue
6.26x
vs Biotechnology peers
Updated Oct 24, 2026
Enterprise to EBITDA
-17.19x
vs Biotechnology peers
Updated Oct 24, 2026
Gross Margin
50.59%
vs Biotechnology peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 42.05%.Updated Oct 24, 2026
Profit Margin
-39.51%
vs Biotechnology peers
Updated Oct 24, 2026
Operating Margin
-50.04%
vs Biotechnology peers
Updated Oct 24, 2026
Return on Assets (TTM)
-4.47%
vs Biotechnology peers
Updated Oct 24, 2026
Return on Equity (TTM)
-6.58%
vs Biotechnology peers
Updated Oct 24, 2026
Revenue (TTM)
219.42MCNY
32.91M · vs all stocks (USD)
Updated Oct 24, 2026
Revenue per Share (TTM)
2.00CNYUpdated Oct 24, 2026
Quarterly Revenue Growth
22.50%
vs Biotechnology peers
Updated Oct 24, 2026
Gross Profit (TTM)
92.27MCNY
13.84M · vs all stocks (USD)
Updated Oct 24, 2026
EBITDA (TTM)
-79.87MCNY
-11.98M · vs all stocks (USD)
Updated Oct 24, 2026
Net Income (TTM)
-86.69MCNY
-13.00M · vs all stocks (USD)
Updated Oct 24, 2026
Quarterly Earnings Growth (YoY)
25.62%
vs Biotechnology peers
Updated Oct 24, 2026
Operating Cash Flow (TTM)
-37.73MCNY
-5.66M · vs all stocks (USD)
Updated Oct 24, 2026
Levered Free Cash Flow (TTM)
-47.79MCNY
-7.17M · vs all stocks (USD)
Updated Oct 24, 2026
Payout Ratio
127.92%
vs Biotechnology peers
Updated Oct 24, 2026
Minority Interest (Equity)
7.18MCNYFY2025 · Dec 31, 2025
Revenue
193.52MCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
105.65MCNYFY2025 · Dec 31, 2025
Gross Profit
87.87MCNYFY2025 · Dec 31, 2025
Operating Income
-120.36MCNY
-18.05M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-106.56MCNYFY2025 · Dec 31, 2025
Income Tax Expense
4.77MCNYFY2025 · Dec 31, 2025
Net Income
-111.33MCNYFY2025 · Dec 31, 2025
EBIT
-105.59MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-74.07MCNYFY2025 · Dec 31, 2025
Research & Development
77.37MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
22.82MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
2.34MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
1.44MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
966.06KCNYFY2025 · Dec 31, 2025
EPS (Basic)
-0.9770CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-0.9770CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
109.94MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
109.94MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-111.33MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
3.92MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-122.10MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-156.39MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
161.27MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-111.33MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
4.02MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-14.60MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-196.51KCNYFY2025 · Dec 31, 2025
Capital Expenditures
-34.29MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-1.49BCNYFY2025 · Dec 31, 2025
Sale of Investments
1.53BCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
3.58MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
4.00MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-6.00MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-257.44KCNYFY2025 · Dec 31, 2025
Other Financing Charges
-35.63MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-37.88MCNYFY2025 · Dec 31, 2025
Shares Outstanding
112.49MSharesUpdated Oct 24, 2026
Float Shares
109.44MSharesUpdated Oct 24, 2026
% Held by Insiders
67.18%
vs all stocks
Updated Oct 24, 2026
% Held by Institutions
6.11%
vs all stocks
Updated Oct 24, 2026
Total Cash (MRQ)
756.03MCNY
113.39M · vs all stocks (USD)
Updated Oct 24, 2026
Total Cash per Share (MRQ)
6.88CNYUpdated Oct 24, 2026
Total Debt (MRQ)
43.35MCNY
6.50M · vs all stocks (USD)
Updated Oct 24, 2026
Total Debt to Equity (MRQ)
0.0327x
vs Biotechnology peers
Updated Oct 24, 2026
Current Ratio (MRQ)
14.79x
vs Biotechnology peers
Updated Oct 24, 2026
Book Value per Share (MRQ)
11.99CNYUpdated Oct 24, 2026
Total Assets
1.50BCNY
224.48M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.03BCNYFY2025 · Dec 31, 2025
Total Liabilities
138.47MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
463.33MCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
64.40MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
74.07MCNYFY2025 · Dec 31, 2025
Cash
161.28MCNYFY2025 · Dec 31, 2025
Cash Equivalents
71.00CNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
161.28MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
420.14MCNYFY2025 · Dec 31, 2025
Accounts Receivable
58.78MCNYFY2025 · Dec 31, 2025
Inventory
48.77MCNYFY2025 · Dec 31, 2025
Accounts Payable
19.39MCNYFY2025 · Dec 31, 2025
Short-term Debt
9.91MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
1.19MCNYFY2025 · Dec 31, 2025
Long-term Debt
4.54MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
124.56KCNYFY2025 · Dec 31, 2025
Common Stock (Book)
112.49MCNYFY2025 · Dec 31, 2025
Retained Earnings
-123.84MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.36BCNY
203.72M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
47.67MCNYFY2025 · Dec 31, 2025
52-Week Low
14.42CNYUpdated Oct 24, 2026
52-Week High
33.67CNYUpdated Oct 24, 2026
52-Week Change
-33.01%
vs all stocks
Updated Oct 24, 2026
Beta
0.7730x
vs all stocks
Updated Oct 24, 2026
50-Day MA
21.03CNYUpdated Oct 24, 2026
200-Day MA
20.85CNYUpdated Oct 24, 2026
Avg 10-Day Volume
1.89MSharesUpdated Oct 24, 2026
Avg 30-Day Volume
2.09MSharesUpdated Oct 24, 2026
Diluted EPS (TTM)
-0.8000CNYUpdated Oct 24, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.23Receivables vs revenue divergence: 3.55
High gross margins eroded by operating costsNotable
Gross Margin: 0.51Profit Margin: -0.40
Financial Health
Altman Z-Score 9.77: safe zoneNotable
Altman Z-Score: 9.77
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $32.91M, lower than 95% of all stocks globallySignificant